4.1 Publication Agreements, Review Rights, Compensation & Disclosure

Publication Agreements, Review Rights, Compensation & Disclosure

Agreements That May Apply

A company-sponsored publication may be affected by several documents:

They must be read together. If terms conflict, escalate to the responsible legal, compliance, contracting, or governance function rather than inventing a compromise.

Publication Rights and Multicenter Sequencing

Multicenter CTAs often coordinate site-level publication with the primary pooled report. The purpose can be scientifically legitimate: premature single-site reporting may disclose an incomplete picture, create biased subgroup claims, or interfere with the planned primary analysis.

But the exact rule is contractual. It may allow a site publication after:

• the multicenter paper is published;
• the multicenter paper is submitted or accepted;
• the sponsor or writing group declines to publish;
• a specified period expires;
• a steering committee approves a scientifically distinct analysis.

Do not assume a standard 12-to-18-month pooling clause. Review the signed agreement and protect the investigator's residual right to publish. A clause that permits indefinite suppression should be escalated and evaluated against law, ethics, funder commitments, and publication-practice standards.

Sponsor Review

A sponsor can have legitimate review responsibilities. A prospectively defined review may address:

• factual accuracy against validated data;
• confidential information;
• patentable inventions;
• regulatory or legal risk;
• privacy;
• required safety context;
• compliance with an agreement;
• completeness of sponsor-role and funding disclosure.

Review does not equal editorial ownership. Authors should consider relevant comments but remain responsible for their scientific interpretations and final approval. The sponsor should not remove an unfavorable prespecified result, demand a claim unsupported by the analysis, choose authors for prescribing influence, or impose delay for product positioning.

The duration and process should be reasonable and written. GPP 2022 does not establish a universal 30-day review or 60-to-90-day patent delay. The agreement and circumstances control, subject to the principle of timely dissemination.

Intellectual Property

Public disclosure can affect patent rights, so a limited prepublication review for patentable material can be appropriate. Plan early enough to file without unnecessary delay. A temporary hold should be tied to a real filing activity and the agreed process, not to waiting for a patent to issue or a product to launch.

Separate patent review from copyright. Patent protection concerns inventions before disclosure; copyright and licensing concern expression and reuse of the publication.

Author Agreements

A good author agreement communicates:

• anticipated contributions and authorship criteria;
• that byline status depends on actual contributions;
• author access to relevant information;
• review responsibilities and timelines;
• final approval and accountability;
• disclosure obligations;
• professional writing support;
• data-check responsibilities;
• procedures for withdrawal, unresponsiveness, disputes, or authorship changes;
• expense reimbursement and any compensation policy;
• archiving and communication expectations.

An agreement cannot make a nonqualifying contributor an author. It can, however, create a fair process and give each proposed author the opportunity to meet the criteria.

Compensation

Distinguish payment for authorship from compensation for legitimate work.

Payment merely for placing a name on a byline, endorsing a conclusion, prescribing, or lending prestige is unethical. GPP 2022's official FAQs explain, however, that reasonable compensation for actual publication activities may be permissible in some circumstances. Examples can include steering-committee work, new analysis or interpretation, manuscript review, or patient-partner contributions.

The arrangement must be:

• for defined services, not for a name;
• reasonable and consistent with applicable fair-market-value controls;
• permitted by law, institutional policy, contract, and company policy;
• communicated clearly, preferably in the agreement;
• reported through Open Payments or another transparency system when applicable;
• disclosed to the venue as required.

Compensation does not automatically qualify or disqualify authorship. Apply authorship criteria separately.

Financial and Nonfinancial Disclosure

Publication disclosure may require:

• study funding;
• sponsor role;
• individual financial relationships;
• relevant institutional support;
• patents or intellectual property;
• nonfinancial interests requested by the venue;
• professional writing or editorial support and its funding;
• data-access or analysis roles.

Use the current journal or conference form and each author's own complete disclosure. Do not copy a disclosure from an earlier article without reconfirmation.

Transfer-of-Value Coordination

A payment can be reportable even if it is ethically permissible, and an unreported relationship can still require journal disclosure. Open Payments, EFPIA-related processes, national transparency law, institutional disclosure, and journal disclosure have different scopes.

For each arrangement, preserve:

• agreement and statement of work;
• service description;
• dates and attendees;
• recipient details;
• invoices and expense records;
• fair-market-value documentation where required;
• reporting classification;
• publication disclosure.

Do not assume professional writing activity is always excluded from Open Payments. CMS says research writing and publication activity is included when it is in the written research agreement or protocol and paid as part of the research payment.

Dispute Scenario

A site investigator wants to publish a single-center analysis before the pooled multicenter report. The correct first steps are to:

1. read the signed CTA and publication policy;
2. determine whether the analysis is scientifically distinct and sufficiently powered;
3. assess risk to the primary report and participant confidentiality;
4. use the stated governance and escalation process;
5. preserve the investigator's contractual publication right when any defined coordination period ends.

It is not defensible to announce that a “standard” pooling clause automatically prohibits the work for 18 months.

Safety-Data Scenario

If a sponsor function requests deletion of a prespecified hepatic safety result because it may affect positioning, the request should be rejected and escalated. The manuscript should report the validated finding with appropriate context. Sponsor review may improve factual accuracy, but it may not turn the scientific record into a selective marketing narrative.